In an ICB-treated validation cohort, CD44 levels in the tumour compartment predicted PFS upon multivariate analysis after adjusting for performance status, baseline liver metastasis and LIPI score (HR 0.62, 95%CI 0.40–0.96 and p = 0.035). This evidence concerns the gene CD44 and neoplasm.